BRISBANE, Calif. & RICHMOND, Va.--(BUSINESS WIRE)--Tercica, Inc., (Nasdaq:TRCA) and Insmed Incorporated (Nasdaq:INSM) today announced that Tercica, Insmed and Genentech, Inc. (NYSE:DNA) have entered a Settlement, License and Development Agreement that resolves all outstanding litigation between the companies, including the patent infringement suits brought by Tercica and Genentech against Insmed in the United States (N.D. Cal.) and United Kingdom, and the unfair business practices suit (E.D. Virginia). The key elements of this settlement are:
